A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B

American Journal of Clinical Nutrition

Volumn 105, Issue 5, 2017, Pages 1239-1247

  Ho, Hoang Vi Thanh ^a,d   Jovanovski, Elena ^a,d   Zurbau, Andreea ^a,d   Mejia, Sonia Blanco ^a,d   Sievenpiper, John L ^a,b,d   Au Yeung, Fei ^a,d   Jenkins, Alexandra L ^a   Duvnjak, Lea ^c   Leiter, Lawrence ^a,b,d   Vuksan, Vladimir ^a,b,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c University of Zagreb   (Croatia)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

CVD risk reduction; Konjac glucomannan; LDL cholesterol; Non HDL cholesterol and apolipoprotein B; Systematic review and metaanalysis

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KONJAC GLUCOMANNAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; UNCLASSIFIED DRUG; (1-6)-ALPHA-GLUCOMANNAN; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; DIETARY FIBER; FOLLOW UP; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; ADULT; AMORPHOPHALLUS; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; CHILD; DIET; FEMALE; MALE; MIDDLE AGED; PHARMACOLOGY; THERAPEUTIC USE;

ADULT; AMORPHOPHALLUS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; DIETARY FIBER; FEMALE; HUMANS; MALE; MANNANS; MIDDLE AGED;

EID: 85019853721     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.116.142158     Document Type: Article

References (43)

1. Brown L, Rosner B, Willett WC, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42
2. Vuksan V, Jenkins AL, Rogovik AL, Fairgrieve CD, Jovanovski E, Leiter LA. Viscosity rather than quantity of dietary fibre predicts cholesterol-lowering effect in healthy individuals. Br J Nutr 2011;106: 1349-52
3. Jenkins DJ, Kendall CW, Vuksan V. Viscous fibers, health claims, and strategies to reduce cardiovascular disease risk. Am J Clin Nutr 2000; 71:401-2
4. Vuksan V, Sievenpiper JL, Owen R, Swilley JA, Spadafora P, Jenkins DJ, Vidgen E, Brighenti F, Josse RG, Leiter LA, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9-14
5. Chua M, Baldwin TC, Hocking TJ, Chan K. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol 2010;128:268-78
6. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2010;8(10):1798.
7. Summary of Health Canada's assessment of a health claim about a polysaccharide complex (glucomanna, xanthan gum, sodium alginate) and cholesterol lowering [updated May 2016]. Ottawa (Canada): Bureau of Nutritional Sciences, Food Directorate, Health Products and Food Branch, Health Canada; 2016.
8. Summary of Health Canada's assessment of a health claim about a polysaccharide complex (glucomanna, xanthan gum, sodium alginate) and a reduction of the post-prandial blood glucose response [updated May 2016]. Ottawa (Canada): Bureau of Nutritional Sciences, Food Directorate, Health Products and Food Branch, Health Canada; 2016.
9. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr 2008;88:1167-75
10. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J Jr., Grover S, Gupta M, et al. Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016.
11. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67
12. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane. org.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
14. Guidance for Industry: evidence-based review system for the scientific evaluation of health claims - final. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition; 2009. Available from: https://www.fda. gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/ labelingnutrition/ucm073332.htm.
15. Kris-Etherton PM, Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Am J Clin Nutr 1997;65(5 Suppl):1590S- 1596S
16. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001;286:944-53
17. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. Chichester (UK): John Wiley & Sons, Ltd.; 2009.
18. A summary of error propagation [Internet]. Cambridge (MA): Harvard University; 2007. [cited 2016 Nov 3]. Available from: http://ipl.physics.harvard.edu/wp-uploads/2013/03/PS3-Error-Propagation-sp13.pdf.
19. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31:140-9
20. Zhang MY, Huang CY,Wang X, Hong JR, Peng SS. The effect of foods containing refined konjac meal on human lipid metabolism. Biomed Environ Sci 1990;3:99-105
21. Cairella M, Marchini G. [Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients.] Clin Ter 1995;146:269-74 (in Italian)
22. Kaats GR, Bagchi D, Preuss HG. Konjac glucomannan dietary supplementation causes significant fat loss in compliant overweight adults. J Am Coll Nutr 2015 Oct 22 (Epub ahead of print; DOI: 10.1080/ 07315724.2015.1009194).
23. Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, Adamji J. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes 2013 Dec 30 (Epub ahead of print; DOI: 10.1155/2013/610908).
24. Salvatoni A, Bosetti G, Gambarini G. Lipid profile and excess body weight in obese children: effect of a dietary drug supplement (glucomannan vs detastranum). Ped Oggi 1991;11:243-5
25. Vita PM, Restelli A, Caspani P, Klinger R. [Chronic use of glucomannan in the dietary treatment of severe obesity.] Minerva Med 1992; 83:135-9 (in Italian)
26. Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr 1995;61:5085-9
27. Chen HL, Sheu WH, Tai TS, Liaw YP, Chen YC. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects-a randomized double-blind trial. JAm Coll Nutr 2003;22:36-42
28. Guardamagna O, Abello F, Cagliero P, Visioli F. Could dyslipidemic children benefit from glucomannan intake? Nutrition 2013;29:1060-5
29. Martino F, Martino E, Morrone F, Carnevali E, Forcone R, Niglio T. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis 2005;15:174-80
30. Martino F, Puddu PE, Pannarale G, Colantoni C, Martino E, Niglio T, Zanoni C, Barilla F. Low dose chromium-polynicotinate or policosanol is effective in hypercholesterolemic children only in combination with glucomannan. Atherosclerosis 2013;228:198-202
31. Vido L, Facchin P, Antonello I, Gobber D, Rigon F. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol 1993;28:133-6
32. Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes: a randomized controlled metabolic trial. Diabetes Care 1999;22:913-9
33. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289-93
34. Wood RJ, Fernandez ML, Sharman MJ, Silvestre R, Greene CM, Zern TL, Shrestha S, Judelson DA, Gomez AL, Kraemer WJ, et al. Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism 2007;56:58-67
35. Yoshida M, Vanstone CA, Parsons WD, Zawistowski J, Jones PJ. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur J Clin Nutr 2006;60:529-37
36. Ho HV, Sievenpiper JL, Zurbau A, Mejia SB, Jovanovski E, Au-Yeung F, Jenkins AL, Vuksan V. A systematic review and meta-analysis of randomized controlled trials of the effect of barley b-glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction (i-iv). Eur J Clin Nutr 2016;70:1239-45
37. Ho HV, Sievenpiper JL, Zurbau A, Mejia SB, Jovanovski E, Au- Yeung F, Jenkins AL, Vuksan V. The effect of oat b-glucan on LDLcholesterol, non-HDL-cholesterol, and apoB for CVD risk reduction: a systematic review and meta-analysis of randomized controlled trials. Br J Nutr 2016;116:1369-1382
38. Vuksan V, Sievenpiper JL, Xu Z, Wong EY, Jenkins AL, Beljan- Zdravkovic U, Leiter LA, Josse RG, Stavro MP. Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr 2001;20(5 Suppl):370S-80S; discussion: 81S-3S
39. Barsanti L, Passarelli V, Evangelista V, Frassanito AM, Gualtieri P. Chemistry, physico-chemistry and applications linked to biological activities of beta-glucans. Nat Prod Rep 2011;28:457-66
40. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-43
41. Lazaridou AB, Biliaderis CG. Molecular aspects of cereal b-glucan functionality: physical properties, technological applications, and physiological effects. J Cereal Sci 2007;46:101-18
42. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88:2399-403
43. Tobin KA, Ulven SM, Schuster GU, Steineger HH, Andresen SM, Gustafsson JA, Nebb HI. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem 2002;277: 10691-7.